Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Bilton, P. Robinson, P. Cooper, J. Kolbe, C. G. Gallagher, H. Fox, B. Charlton (London, United Kingdom; Melbourne, Sydney, Australia; Auckland, New Zealand; Dublin, Ireland). Inhaled dry powder mannitol in cystic fibrosis (CF): Microbiology results from the 6 month double-blind CF301 study. Eur Respir J 2010; 36: Suppl. 54, 3500

Member's Comments

No comment yet.

Related content which might interest you: Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study Source: Eur Respir J 2011; 38: 1071-1080 Year: 2011 LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study. Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 LATE-BREAKING ABSTRACT: Randomised, double blind, placebo-controlled phase III study of inhaled dry powder mannitol in cystic fibrosis (CF) Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Inhaled mannitol for non-cystic fibrosis bronchiectasis - results of a 12 month, multi-centre, double-blind, controlled study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Source: Eur Respir J, 51 (1) 1702053; 10.1183/13993003.02053-2017 Year: 2018 Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013 Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study Source: ERJ Open Res, 6 (4) 00132-2020; 10.1183/23120541.00132-2020 Year: 2020 RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Source: Eur Respir J, 51 (1) 1702052; 10.1183/13993003.02052-2017 Year: 2018 Inhaled mannitol in cystic fibrosis: clinical experience in Verona CF centre Source: Virtual Congress 2020 – New insights into respiratory physiotherapy Year: 2020 Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation Source: Eur Respir J 2015; 45: 541-544 Year: 2015 Inhaled mannitol as treatment for children with cystic fibrosis Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease Year: 2008 Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Prevalence of bronchoconstriction in patients with bronchiectasis assessed prior to treatment with a dry powder preparation of mannitol Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007 Prospective follow up over 1 year with N2 multiple breath washout (MBW) in children with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy Year: 2020